Comparative Pharmacology
Head-to-head clinical analysis: CYTADREN versus EXEMESTANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTADREN versus EXEMESTANE.
CYTADREN vs EXEMESTANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglutethimide inhibits the conversion of cholesterol to pregnenolone, thereby blocking adrenal steroidogenesis. It also inhibits aromatase, reducing estrogen synthesis.
Irreversible steroidal aromatase inhibitor; binds to the substrate-binding site of aromatase, causing permanent inactivation of the enzyme. Reduces estrogen synthesis by inhibiting conversion of androgens to estrogens.
200 mg orally once daily
25 mg orally once daily after a meal.
None Documented
None Documented
Terminal elimination half-life: 3–4 hours in adults with normal renal function; prolonged to 8–12 hours in end-stage renal disease.
Clinical Note
moderateExemestane + Digoxin
"Exemestane may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateExemestane + Digitoxin
"Exemestane may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateExemestane + Deslanoside
"Exemestane may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateExemestane + Acetyldigitoxin
"Exemestane may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing. Steady state is achieved after 7 days.
Renal: ~60% as unchanged drug; biliary/fecal: ~25% as metabolites; minor via respiration.
Primarily hepatic metabolism (CYP3A4 and aldoketoreductases) with fecal excretion of metabolites (approximately 80-90%) and renal excretion of unchanged drug and metabolites (approximately 10-20%).
Category C
Category D/X
Aromatase Inhibitor
Aromatase Inhibitor